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distribution within the renal cortex 
refl ects some gradient of oxygen tension 
was not addressed by Paliege  et al. 12 but 
it may appear unlikely, since protein levels 
of HIF-2  were similar in all portions of 
the renal cortex. Th us, HIF-2  was found 
predominantly in interstitial cells of the 
renal cortex. In addition, HIF-2  was 
detected in some scattered endothelial 
and glomerular cells. As the key fi nding, 
there was a marked overlap of EPO- and 
HIF-2  -positive cells: between 83 and 
91 % of EPO-producing interstitial cells 
also stained positive for HIF-2  ; the 
degree of coexpression was slightly higher 
in the deeper than in the more superfi cial 
cortex. Th us, although the vast majority of 
EPO-positive cells also expressed HIF-2  , 
there was apparently a subset of EPO-
expressing cells that did not stain for HIF-2  . 
Whether this fi nding was based on a sen-
sitivity issue of HIF-2  detection or may 
indicate that EPO-producing cells consist 
of two sub-populations — the larger one 
being HIF-2  -dependent and the smaller 
one being HIF-2  -independent — was not 
addressed by Paliege  et al. 12 
 Conversely to HIF-2  , HIF-1  was 
detected in epithelial cells, and there was 
no colocalization with EPO-expressing 
interstitial cells. Th us, the fi ndings of this 
localization study confi rm previous func-
tional evidence indicating that HIF-2  is 
the major factor in oxygen-dependent EPO 
expression. Although the absence of HIF-
1  from EPO-expressing cells of the renal 
cortex excludes a functional relevance of 
HIF-1  for a direct control of EPO tran-
scription, HIF-1  is well able to drive EPO 
expression in extrarenal tissues. 13,14 
 Paliege  et al. 12 furthermore attempted to 
characterize the nature of HIF-2  - and 
EPO-coexpressing interstitial cells. As a 
marker for interstitial fi broblasts of the 
renal cortex, they used ecto-5  -nucleoti-
dase. 10 Most HIF-2  - and EPO-positive 
cells also stained for ecto-5  -nucleotidase, 
whereas no coexpression with the den-
dritic-cell marker major histocompatibility 
complex II was detected, suggesting — but 
not proving — that the oxygen-sensitive 
interstitial cells of the renal cortex mainly 
represent fi broblasts ( Figure 1 ). 
 In summary, the convincing localiza-
tion study by Paliege  et al. 12 now adds the 
last piece to the puzzle and provides a 
 convincing — anatomical — basis for what 
we had expected from functional studies: 
HIF-2  is an indispensible prerequisite for 
oxygen-dependent EPO expression in the 
adult kidney. 
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 KDIGO guideline for the care 
of kidney transplant recipients 
will be resource challenged 
 Francis L.  Delmonico 1 
 The Executive Summary of the KDIGO Clinical Practice Guideline for the 
Care of Kidney Transplant Recipients is presented in this issue of  Kidney 
International .  This guideline will require careful attention for 
implementation in the context of available resources within each 
country, especially those with underdeveloped economies. 
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of Kidney Transplant Recipients is pre-
sented to the international community. 
The complete report, including the 
rationale and references for each recom-
mendation, is to be published in the 
 American Journal of Transplantation 
( AJT ). 2 Th e complete report is also avail-
able on the websites of KDIGO (Kidney 
Disease: Improving Global Outcomes) 
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and Th e Transplantation Society (TTS). 
Th e presentation of such a guideline is 
timely for both transplantation services 
in established centers and those that are 
emerging in many countries throughout 
the world. 
 Th is is not the fi rst venture of KDIGO. 
Important KDIGO documents have been 
assembled regarding hepatitis C and min-
eral and bone disorders in chronic kidney 
disease patients. 3,4 
 A KDIGO eff ort was also responsible 
for the Lisbon Conference held in Febru-
ary 2006 5 that preceded this current 
KDIGO submission. Th e Executive Sum-
mary 1 makes no mention of the report 
from that conference, but an extensive 
document was developed with recom-
mendations to improve the outcomes of 
kidney transplant recipients worldwide. 
Th e Lisbon Conference focused on car-
diovascular disease; cancer and infection; 
anemia, bone disease, reproductive issues, 
growth and development; graft  mainte-
nance; and the role of estimated glomeru-
lar fi ltration rate in monitoring kidney 
function aft er transplantation. 5 
 Th e full and current KDIGO docu-
ment 2 was neither drafted by an 
exclusive American authorship nor 
intended to primarily infl uence Ameri-
can physicians. Th us, notwithstanding 
the concurrent  AJT publication, the 
guideline is appropriately available by 
executive summary in  Kidney Interna-
tional and targeted to a broad readership. 
Country liaisons of TTS will be fur-
nished with the complete document, and 
so will all transplant clinicians, through 
a TTS mailing to its membership. 
 Th e value of this Executive Summary 1 
for all transplant clinicians, especially 
those practicing in underdeveloped 
countries, cannot be understated. Th e 
most challenging aspect of sustaining a 
transplant program in an underdevel-
oped country is the availability of immu-
nosuppressive medications for the 
transplant recipient. Th e section of this 
guideline on strategies to reduce cost 
provides a useful prescription from 
experienced transplant physicians. Th ere 
is also a sensible recommendation not to 
use generic compounds that have not 
been certifi ed by an independent regula-
tory agency, although it is well recog-
nized that generic preparations are 
commonplace. 
 The goal of this KDIGO exercise now 
reported in  Kidney International 1 was 
to compile comprehensive evidence-
based practice guidelines, with each 
recommendation graded for strength 
and overall quality of evidence. How-
ever, not all of the recommendations 
may be well received. For example, the 
recommendation that an interleukin-2 
receptor antagonist (IL2-RA) be the 
first-line induction therapy is highly 
controversial. The authors give this rec-
ommendation a 1B grade, based on 
 ‘ moderate quality of evidence, ’ indicat-
ing that  ‘ most patients should receive 
the recommended course of action. ’ 
Further,  ‘ the recommendation can be 
adopted as a policy in most situations. ’ 
There are those who would quarrel with 
this recommendation and whether such 
a recommendation applies equally to 
matched living-donor and deceased-
donor transplants. The guideline does 
not distinguish recommendations by 
the donor source. Much of the kidney 
transplantation  experience in the world 
occurs through living donation, yet 
the data applicable to IL2-RA were 
derived mainly from deceased-donor 
studies. The cost of an anti-IL2-RA 
preparation in developing countries 
that are exclusively using living donors 
could seemingly be avoided. Finally, 
the Roche IL2-RA preparation is evi-
dently being suspended, leaving only 
Novartis ’ s Simulect, which may have 
limited availability. 
 Finally, careful attention to this guide-
line will be required by transplant physi-
cians in each country, given their 
particular resources to perform kidney 
transplantation. With that well under-
stood, this set of KDIGO guidelines can 
serve the international community well. 
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